AI assistant
Exicon Co., Ltd. — Proxy Solicitation & Information Statement 2016
Feb 23, 2016
Preview isn't available for this file type.
Download source fileCopenhagen, 2016-02-23 14:53 CET (GLOBE NEWSWIRE) -- Exiqon A/S (Nasdaq
Copenhagen: “EXQ”) calls for the ordinary general meeting to be held on
Wednesday 16 March 2015 at 3 pm (CET) at the company’s address, Skelstedet 16,
2950 Vedbaek, Denmark. A copy of the notice with the complete proposals is
attached hereto and can also be seen at www.exiqon.com.
Additional information
Lars Kongsbak, CEO, phone +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, phone +45 4566 0888 (cell: +45 4090 2131)
About Exiqon
At Exiqon, we advance the research of when and where genes are expressed. We
empower scientists across the world with best-in-class products and
user-friendly business solutions designed to transform workflows in our
industry. Exiqon operates in two business areas: Exiqon Life Sciences is a
leading provider of flexible solutions for gene expression analysis. Academia,
biotech and pharmaceutical companies around the world use Exiqon’s research
products to make ground-breaking discoveries. Exiqon Diagnostics collaborates
with diagnostic and pharmaceutical companies to develop novel molecular
diagnostic tests for early detection of diseases, which can help physicians
make better treatment decisions. Exiqon is listed on Nasdaq Copenhagen. For
more information about us, please visit www.exiqon.com